Product name: Ilexsaponin B1
Synonym name:
Catalogue No.: BP1761
Cas No.: 109008-27-7
Formula: C₄₁H₆₆O₁₃
Mol Weight: 766.966
Botanical Source: llexhainanensis Merr(Hainan holly leaf); Ilex pubescens
Physical Description:
Type of Compound:

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
The product could be supplied from milligrams to grams. Inquire for bulk scale.
We provide solution to improve the water-solubility of compounds, thereby facilitating the variety of activity tests and clinic uses.

For Reference Standard and R&D, Not for Human Use Directly.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Ilexsaponin B1 is a triterpene saponin derived from plants of the genus Ilexsaponin. Due to its diverse biological activities and potential medicinal value, it has attracted widespread attention in the field of natural product pharmacology in recent years. Plants of the genus Eugene are widely used in traditional Chinese medicine for purposes such as clearing heat and detoxifying, reducing inflammation and relieving pain. As one of its key chemical components, Eugene saponin B1 demonstrates significant anti-tumor, anti-inflammatory, and immunomodulatory activities, especially showing unique potential in the treatment of malignant tumors such as lung cancer.

As one of the malignant tumors with the highest incidence and mortality rates worldwide, lung cancer urgently needs to develop new treatment strategies and drugs. Hairy holly saponin B1 demonstrates multiple mechanisms of action by regulating multiple signaling pathways and key molecular targets, inhibiting lung cancer cell proliferation, inducing apoptosis, and suppressing tumor metastasis, making it a hot topic in natural anticancer drug research. This paper will systematically review the chemical structure and physicochemical properties of Eugene B1, plant origin and extraction process, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, combined with its potential in lung cancer treatment, to explore its future clinical development prospects.

Chemical structure and physicochemical properties

Hairy holly saponin B1 is a typical triterpene saponin with a molecular formula of C_42H_66O_14 and a molecular weight of 766.9660. Its structure includes a pentacyclic triterpene nucleus, which connects multiple glycosyl residues to form a typical saponin structure. The compound has a LogP value of 2.4519, showing moderate lipid solubility that facilitates cell membrane penetration. TPSA (Topological Polar Surface Area) is 215.8300, indicating it has strong polar groups, which may affect the permeability of its biofilm and its ability to bind to targets.

Water solubility is 0.0759, making it a low-solubility compound, suggesting that its dissolution and absorption in the body may be limited. The low permeability of Hilocylin B1 at the blood-brain barrier suggests its limited distribution in the central nervous system, which may reduce the risk of CNS toxicity. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenicity test result was 0.0, indicating that this compound has no significant mutagenicity and is relatively safe.

Plant Origins and Extraction Methods

Ilex pubescens saponin B1 is mainly found in plants of the genus Ilex pubescens, especially Ilex pubescens and its close relatives. Plants of the genus Holly are widely distributed in southern China and Southeast Asia, and have traditionally been used to treat cardiovascular diseases, inflammation, and tumors.

Common methods for extracting hairy holly saponin B1 include solvent extraction, liquid-liquid partitioning, column chromatography, and high-performance liquid chromatography (HPLC) separation. Generally, ethanol or methanol is first used for rough extraction, followed by separation of the aqueous and organic phases to remove fat-soluble impurities, followed by separation and purification using silica gel columns or C18 reversed phase columns. In recent years, ultrasound-assisted extraction and microwave-assisted extraction technologies have been introduced to improve extraction efficiency and purity. Additionally, temperature and pH must be controlled during preparation to prevent degradation of saponin structures.

Pharmacological activity research

Anti-lung cancer activity

Velvet saponin B1 exhibits significant inhibitory effects in various lung cancer cell lines. In vitro experiments have shown that this compound can inhibit the proliferation of lung cancer cells, induce cell cycle arrest, and promote apoptosis. Its antitumor effects are closely related to the regulation of multiple signaling pathways, including inhibition of STAT3, MAPK1, and PI3K/Akt pathways, regulation of BCL2 family protein expression, and promotion of activation of CASP9-mediated apoptotic pathways.

Anti-inflammatory and immunomodulatory

Velvet saponin B1 has good anti-inflammatory activity, inhibiting the expression of inflammatory factors such as TNF-α, IL-6, and NF-κB, thereby reducing inflammatory responses. Its immunomodulatory effects mainly manifest as modulating the functions of macrophages and lymphocytes, enhancing the body's immune surveillance capabilities, and providing auxiliary support for its anti-tumor effects.

Other pharmacological effects

In addition to fighting lung cancer and inflammation, holly saponin B1 also exhibits certain antioxidant activity, scavenging free radicals and protecting cells from oxidative damage. Additionally, some studies indicate that it has protective effects on the cardiovascular system and may improve myocardial injury by modulating the PPARγ signaling pathway.

Mechanism of action and molecular targets

The anti-lung cancer effect of Mao Dongqing saponin B1 involves multiple molecular targets and signaling pathways, with the specific mechanisms as follows:

• BCL2 family protein regulation: By downregulating the expression of the anti-apoptotic protein BCL2, mitochondrial pathway-mediated apoptosis is promoted.
• STAT3 signaling pathway inhibition: Inhibits STAT3 phosphorylation and nuclear translocation, blocks its transcriptional regulatory functions, and suppresses tumor cell proliferation and immune escape.
• ESR2 (estrogen receptor β) regulation: modulates ESR2 expression and influences hormone-dependent growth of tumor cells.
• MAPT (microtubule-associated protein Tau) regulation: affects cytoskeletal stability and inhibits tumor cell migration and invasion.
• PIK3CG (PI3Kγ) inhibition: blocks the PI3K/Akt signaling pathway, suppressing cell survival and proliferation.
• RELA (NF-κB p65 subunit) inhibition: suppresses the NF-κB signaling pathway, reducing the expression of inflammatory and tumor-related genes.
• Regulation of MAPK1 and MAPK8: Regulation of the MAPK signaling pathway, affecting cell proliferation and stress responses.
• CASP9 activation: initiates the mitochondrial pathway in the apoptotic cascade.
• PPARG activation: regulates cellular metabolism and inflammatory responses, enhancing anti-tumor immunity.

The synergistic effect of these targets gives hairy saponin B1 multi-target and multi-pathway advantages in lung cancer treatment, helping to overcome resistance issues with single-target drugs.

Druggability evaluation and pharmacokinetics

The druggability parameters of Hollyposide B1 indicate that it has certain development potential. A larger molecular weight (766.9660) and higher polarity (TPSA 215.8300) may limit its oral bioavailability, but a moderate LogP value (2.4519) favors cell membrane permeability. Its low water solubility (0.0759) suggests the need to improve dissolution and absorption rate through formulation optimization methods such as nanocarriers and liposomes.

The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects. Negative hERG channel inhibition indicates good cardiac safety, while a negative Ames test supports genotoxic safety. Currently, in vivo pharmacokinetic studies are limited. Preliminary data indicate that this compound is widely distributed in vivo, metabolized mainly through hepatic enzyme systems, has a moderate half-life, and is suitable for further pharmacokinetic optimization and formulation development.

Prospects and outlooks for clinical applications

As a natural product with multi-target anti-lung cancer activity, Maoholgenin B1 possesses good pharmacological activity and a safety foundation, demonstrating significant clinical development potential. Future research should focus on:

1. In-depth pharmacokinetics and toxicology research: systematically evaluating in vivo metabolic pathways, drug interactions, and long-term safety.
2. Dosage form optimization and drug delivery route exploration: Novel formulations such as nanotechnology and liposomes are used to improve bioavailability and targeting.
3. Combination therapy strategy: Combine with existing chemotherapy drugs, targeted drugs, or immune checkpoint inhibitors to enhance anti-tumor effects and reduce resistance risk.
4. Preclinical and clinical trial design: Establish appropriate animal models to verify antitumor activity and safety, gradually advancing to clinical trial stages.
5. Deepening Mechanistic Research: Using multi-omics techniques to reveal the molecular networks of its effects, identify potential biomarkers, and guide personalized treatment.

In summary, as an emerging candidate molecule for natural product drug development, Holly saponin B1 has broad application prospects and deserves sustained attention and investment from the research and pharmaceutical industries.

Conclusion

As an important triterpene saponin in the genus Ilegus, Puffer's saponin B1 shows significant potential in the treatment of malignant tumors such as lung cancer due to its unique chemical structure and multi-target pharmacological activity. Its anti-tumor mechanism involves multiple signaling pathways and key molecular targets, with multiple effects including apoptosis induction, proliferation inhibition, and anti-inflammatory immune regulation. Druggability evaluations showed that the compound was safe, but its water solubility and bioavailability still needed optimization. In the future, through in-depth pharmacokinetic research, dosage form innovation, and preclinical validation, it is expected that Maoholgenin B1 will be promoted for clinical application, providing new treatment options for lung cancer patients. As a vital resource for drug discovery, research on Isothoside B1 not only enriches the natural anti-cancer drug library but also provides strong support for multi-target anti-tumor strategies.